John O. Mascarenhas, MD, discusses limitations with JAK inhibitors in myelofibrosis.
John O. Mascarenhas, MD, associate professor of medicine, hematology, and medical oncology at the Icahn School of Medicine at Mount Sinai; director of the Adult Leukemia Program; and leader of Clinical Investigation within the Myeloproliferative Disorders Program at Mount Sinai, and a member of the Tisch Cancer Institute, discusses limitations with JAK inhibitors in myelofibrosis.
Myelofibrosis is a complex hematopoietic malignancy that often results in multiple hematologic events, including anemia, thrombocytopenia, increased blasts, transformation to acute leukemia, and spleen/symptom burden, says Mascarenhas.
Notably, the JAK inhibitors ruxolitinib (Jakafi) and fedratinib (Inrebic) have been fundamental in treating certain aspects of the disease, such as spleen ailments, Mascarenhas says. However, JAK inhibitors cannot treat anemia or alter the natural history of the disease.
As such, ongoing research efforts are evaluating a host of therapies that could potentially be used in the salvage setting for patients who progress on or are refractory to JAK inhibitors, Mascarenhas concludes.